Cocrystal Pharma (COCP) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

$105,000.00

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$3.2M

Net income growth (year over year)

−53.97%

Net margin

—

Return on equity

−311.68%

EPS (trailing twelve months)

−$0.75

Book value per share

$0.08

P/E (trailing twelve months)

—

Price to book

19.93

Debt to assets

77.54%

Payout ratio

—

Dividend yield

—

Company profile

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

• How do I buy stock in Cocrystal Pharma (COCP)?

  COCP trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.